What do systematic reviews say?

Rifampicin vs isoniazid

It is very uncertain whether rifampicin changes active TB compared with isoniazid (very low certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 0.81 [0.47, 1.4]
  1 study · 332 participants
  Very low

Rifapentine plus isoniazid weekly vs isoniazid

Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 0.44 [0.18, 1.07]
  1 study · 7731 participants
  Moderate

Rifampicin plus isoniazid vs isoniazid

It is very uncertain whether rifampicin plus isoniazid changes active TB compared with isoniazid (very low certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 1.08 [0.65, 1.79]
  1 study · 328 participants
  Very low

Rifampicin plus pyrazinamide vs isoniazid

It is very uncertain whether rifampicin plus pyrazinamide changes active TB: compared with isoniazid (very low certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 1.32 [0.42, 4.13]
  2 studies · 176 participants
  Very low

Isoniazid prophylaxis vs placebo

Isoniazid prophylaxis may leads to lower active TB compared with placebo (low certainty).

• Isoniazid for preventing tuberculosis in HIV‐infected children 2017 · Cochrane Headline outcomes only
  HR 0.31 [0.11, 0.87]
  1 study · 240 participants
  Low

Isoniazid prophylaxis vs placebo

It is very uncertain whether isoniazid prophylaxis changes active TB compared with placebo (very low certainty).

• Isoniazid for preventing tuberculosis in HIV‐infected children 2017 · Cochrane Headline outcomes only
  RR 0.76 [0.5, 1.14]
  3 studies · 737 participants
  Very low

Intervention not reported

• Patient education and counselling for promoting adherence to treatment for tuberculosis 2012 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in cure or completion of treatment for active TB (low certainty).

• Incentives and enablers to improve adherence in tuberculosis 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.97, 1.13]
  2 studies · 4356 participants
  Low

MVA85A vs placebo

MVA85A showed no clear difference in active tuberculosis: started on tuberculosis treatment compared with placebo (moderate certainty).

• MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
  RR 1.1 [0.92, 1.33]
  3 studies · 3687 participants
  Moderate

MVA85A vs placebo

MVA85A showed no clear difference in active tuberculosis: confirmed by culture or Xpert® MTB/RIF longest… compared with placebo (moderate certainty).

• MVA85A vaccine to enhance BCG for preventing tuberculosis 2019 · Cochrane Headline outcomes only
  RR 0.97 [0.58, 1.62]
  2 studies · 3439 participants
  Moderate